<DOC>
	<DOCNO>NCT01687036</DOCNO>
	<brief_summary>Primary Endpoint Safety tolerability ablation use AFreeze Cryoablation System consist ablation CoolLoop® catheter , steerable sheath cryoconsole Cryo-Caddy assess express number participant Adverse Events ( AEs ) .</brief_summary>
	<brief_title>Cryoablation Atrial Fibrillation Using Novel Cryoablation System</brief_title>
	<detailed_description>Therefore , primary endpoint measurement follow parameter express number participant AE : - deformation catheter loop result entrapment catheter heart difficulty remove catheter visit 3 ( treatment ) - phrenic nerve palsy visit 3 ( treatment ) - onset time course visit 3 ( treatment ) visit 5 ( discharge ) death , pericardial tamponade , valve damage require surgery hemorrhage require transfusion . - onset time course visit 3 ( treatment ) visit 9 ( final visit ) atrioesophageal fistula , sepsis , abscess , endocarditis , stroke , transient ischemic attack , pulmonary vein ( PV ) stenosis require intervention . Secondary Endpoint The following parameter assess express number participant AE/duration time : - feasibility , define ability position catheter proximal part PVs use over-the-wire technique , form cryo-applicator catheter loop operate catheter handle , position-ing loop wall PV antrum deliver cryothermia . - acute efficacy catheter ablation define percentage electrode within PV without measureable signal . - clinical efficacy catheter ablation define freedom Atrial Fibrillation ( AF ) four , eight twelve week ablation . - procedure time define introduction CoolLoop® catheter leave atrium removal CoolLoop® catheter leave atrium termination last cryoapplication . - fluoroscopy time define introduction CoolLoop® catheter leave atrium removal CoolLoop® catheter leave atrium termination last cryoapplication . - cumulative cryoablation time . - onset time course visit 3 ( treatment ) visit 5 ( discharge ) pneumothorax , hemothorax , femoral pseudoaneurysm , arteriovenous fistula , hemorrhage require transfusion .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>age 18 70 year symptomatic paroxysmal AF , accord actual guideline European Society Cardiology , despite treatment least one antiarr hythmic drug least one episode AF within last 3 month document ECG sign date informed consent document patient , indicate patient inform pertinent aspect trial prior study enrollment female subject childbearing potential include , : agree use , able comply , effective contraception without interruption , study enrollment , throughout hospitalization 12 week catheter ablation ( day 0 , visit 3 ) . This apply unless subject commits absolute continued abstinence . The following effective method contraception : Implant , Levonorgestrelreleasing intrauterine system ( IUS ) , Medroxyprogesterone acetate depot , Tubal sterilization , Sexual intercourse vasectomize male partner ; vasectomy must confirm two negative semen analysis , Ovulation inhibitory progesteroneonly pill ( i.e. , desogestrel ) . ( Combined oral contraceptive pill recommend . If subject use combined oral contraception , must switch one method . The increase risk venous thromboembolism ( VTE ) continue 4 6 week stop combined oral contraception . leave atrial diameter &gt; 50 mm assess transthoracic echocardiography , electrical cardioversion perform later seven day onset AF , advance structural heart disease include moderatetosevere valvular stenosis regurgitation , previous myocardial infarction impair leave ventricular systolic function , congenital heart disease , leave ventricular ejection fraction &lt; 45 % sinus rhythm , coronary artery bypass graft surgery within last 3 month . chronic obstructive pulmonary disease treat betasympathomimetic drug , severe respiratory insufficiency , know bleed diathesis intolerance heparin oral anticoagulation , previous AF ablation , leave atrial thrombus , severe comorbidity , hyperthyreosis , condition , include presence laboratory abnormality , would place subject unacceptable risk / participate study confound ability interpret data study , serious medical condition , laboratory abnormality , psychiatric illness , would prevent subject signing Informed Consent Form , pregnant lactating female , severe condition , make patient unsuitable participate study , judge Investigator , patient active another clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Atrial fibrillation</keyword>
	<keyword>Cryoablation</keyword>
</DOC>